Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The transcription factor REST is lost in aggressive breast cancer.

Wagoner MP, Gunsalus KT, Schoenike B, Richardson AL, Friedl A, Roopra A.

PLoS Genet. 2010 Jun 10;6(6):e1000979. doi: 10.1371/journal.pgen.1000979.

2.

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV.

J Clin Oncol. 2008 Sep 1;26(25):4078-85. doi: 10.1200/JCO.2007.13.4429.

3.

Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.

Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, Press MF.

Cancer Res. 2001 Apr 1;61(7):3212-9.

4.
5.

Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors.

Gunsalus KT, Wagoner MP, Meyer K, Potter WB, Schoenike B, Kim S, Alexander CM, Friedl A, Roopra A.

Cancer Res. 2012 Jul 1;72(13):3207-16. doi: 10.1158/0008-5472.CAN-11-1639. Epub 2012 Apr 24.

6.

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE.

Cancer Res. 2007 Sep 1;67(17):8065-80. Erratum in: Cancer Res. 2007 Oct 15;67(20):10097.

7.

The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100).

Shimojo M, Shudo Y, Ikeda M, Kobashi T, Ito S.

Mol Cancer Res. 2013 Oct;11(10):1258-68. doi: 10.1158/1541-7786.MCR-13-0269. Epub 2013 Aug 8.

8.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R.

Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22.

9.

Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.

Dowhan DH, Harrison MJ, Eriksson NA, Bailey P, Pearen MA, Fuller PJ, Funder JW, Simpson ER, Leedman PJ, Tilley WD, Brown MA, Clarke CL, Muscat GE.

Endocr Relat Cancer. 2012 Jul 22;19(4):509-26. doi: 10.1530/ERC-12-0100. Print 2012 Aug.

10.

Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer.

Chen GL, Miller GM.

PLoS One. 2013 Apr 16;8(4):e62217. doi: 10.1371/journal.pone.0062217. Print 2013.

11.

Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ΞΆ, FOXM1, and a gene signature associated with mitosis.

Bergamaschi A, Christensen BL, Katzenellenbogen BS.

Breast Cancer Res. 2011 Jun 29;13(3):R70. doi: 10.1186/bcr2913.

12.

Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.

Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J.

Clin Cancer Res. 2005 Jun 15;11(12):4357-64.

13.

Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.

Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.

PLoS One. 2009;4(3):e4710. doi: 10.1371/journal.pone.0004710. Epub 2009 Mar 9.

14.

Mammary tumor formation and metastasis evoked by a HER2 splice variant.

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M.

Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18.

15.

Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.

Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL.

Breast Cancer Res. 2011 Mar 4;13(2):R24. doi: 10.1186/bcr2839.

17.

The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.

Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG.

Int J Mol Med. 2007 Oct;20(4):605-11.

PMID:
17786294
18.

The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, Russell AJ, Nousch M, Preiss T, Biankin AV, Sutherland RL, Musgrove EA.

Breast Cancer Res. 2008;10(2):R28. doi: 10.1186/bcr1985. Epub 2008 Mar 29.

19.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.

20.

Gene expression patterns associated with p53 status in breast cancer.

Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM.

BMC Cancer. 2006 Dec 6;6:276.

Supplemental Content

Support Center